Predict your next investment

Corporation
HEALTHCARE | Drug Development
alcobra-pharma.com

See what CB Insights has to offer

Stage

IPO | IPO

Date of IPO

11/17/2015

About Alcobra

Alcobra is a pharmaceutical company committed to developing safe and effective products for the treatment of cognitive disorders including ADHD and Fragile X Syndrom.

Alcobra Headquarter Location

Azrieli Triangle Building 39th Floor 132 Derech Menachem Begin

6701101,

Israel

+972 722204661

Latest Alcobra News

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry

Jun 25, 2018

Share this article NEW YORK, June 25, 2018 /PRNewswire/ -- This report analyzes the worldwide markets for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics in US$ Million. Read the full report: https://www.reportlinker.com/p05443604 The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 27 companies including many key and niche players such as: - Alcobra Ltd. Sunovion Announces Top-line Results from Phase II/III Clinical Trial Taisho Conducts Phase II Trial for TS-141 Shire Announces Positive Top-Line Result from Phase III Trial of SHP465-305 Highland Therapeutics Initiates Phase II Trial for HLD100 FDA Advises Hold for Alcobra Phase III Trial MDX for ADHD 6. PRODUCTS INNOVATIONS/INTRODUCTIONS Tris Pharma Introduces Liquid DYANAVEL XR for ADHD Neos Introduces Adzenys XR-ODT Shire Introduces Elvanse Adult®, Stimulant Treatment for Adult ADHD Teva Adds Generic Intuniv® to Existing Line of ADHD Products FDA Approves Pfizer€™s QuilliChew ER„¢ Chewable Tablets Actavis Introduces Generic Version of Intuniv 7. RECENT INDUSTRY ACTIVITY Medgenics Acquires neuroFix Therapeutics Alcobra Ltd. (Israel) Amedra Pharmaceuticals LLC (US) 9. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for ADHD Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 2: World Historic Review for ADHD Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) Table 3: World 14-Year Perspective for ADHD Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III. MARKET Table 4: US ADHD Market: Prices of Select ADHD Drugs (2015) (includes corresponding Graph/Chart) US ADHD Prevalence Rate: Some Major Facts Table 5: ADHD with Co-existing Conditions (includes corresponding Graph/Chart) Major Trends Impacting the US ADHD Therapeutics Market Generics Ruling the Roost in US ADHD Therapeutics Market Table 6: US Market for ADFHD Drugs: Percentage Breakdown of Revenue for Stimulants and Non-stimulants (2015) (includes corresponding Graph/Chart) Adults on the Radar of US ADHD Drugs Manufacturers Table 7: US ADHD Drugs Market: Percentage Breakdown of ADHD Drug Prescriptions by Age Group & Gender (2015) (includes corresponding Graph/Chart) ADHD Drug for Adults: A Trail of Misuse, Addiction and Death More Prescriptions, More Issues More Drugs, More Complications, More Emergency Room Visits Though Small in Number, Deaths Due to ADHD Drug Complications is Rising ADHD in Children: A Case of One Diagnosis Too Many Individual Choices of Healthcare Professionals Influencing ADHD Diagnosis DSM 5„¢ Criteria Clinical Trials Strategic Corporate Development B.Market Analytics Table 22: Rest of World Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 23: Rest of World Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 27 (including Divisions/Subsidiaries - 28) The United States (17) Canada (2) Japan (2) Europe (5) - The United Kingdom (1) - Rest of Europe (4) Middle East (2) Read the full report: https://www.reportlinker.com/p05443604 ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alcobra

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alcobra is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Alcobra Patents

Alcobra has filed 11 patents.

The 3 most popular patent topics include:

  • Piperazines
  • Piperidines
  • Pyridines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/10/2017

4/3/2018

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/10/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/3/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.